Antibodies represent a key position
Nowadays, antibodies are representing a key position in the constantly growing biotechnological pharmaceutical industry. More than 30 antibodies have been worldwide approved as new therapeutic agents and this will tendency will be increasing during the next years. Some of these have already reached block buster status and generated revenues of more than 1 billion EURO. Based on solid know how on the expression of recombinant immunological proteins and fusion proteins in bacteria and mammalian cells, major topics of work in the department are both the development as well as the optimization of economically and pharmaceutically relevant diagnostic and therapeutic agents for clinical application in man and animal.